Paxlovid is one of the strangest line items in American pharmacy pricing. The sticker price is roughly $1,500 for five days of pills, which puts it in specialty-drug territory. Yet a large share of the people who fill it pay nothing, because a federal assistance program that was supposed to be temporary is still running.
That gap is the whole story of what Paxlovid costs. If you know the program exists and enroll, the number is $0. If you walk up to a counter, hand over a card and say nothing, the number is four figures. Every price below was researched on September 3, 2026, from CMS acquisition data effective August 19, 2026 and from live pharmacy and manufacturer pages read the same day.
What Does Paxlovid Cost Without Insurance?
The table compares the ways people actually get Paxlovid. Cash prices come from the Drugs.com Paxlovid price guide read September 3, 2026. Acquisition cost is the CMS National Average Drug Acquisition Cost (NADAC) per tablet effective August 19, 2026, multiplied by the carton contents listed in the FDA-approved label on DailyMed (30, 20 and 11 tablets for the three dose packs). Program prices come from Pfizer’s own PAXCESS page.
| How you get it | Low | Average | High |
|---|---|---|---|
| US Government Patient Assistance Program, uninsured or Medicare or Medicaid | $0 (PAXCESS) | $0 (PAXCESS) | $0 (PAXCESS) |
| Commercial insurance plus Pfizer co-pay card | $0 (PAXCESS) | $0 (PAXCESS) | $0, capped at $1,000 saved per year (PAXCESS) |
| Cash, standard 30-tablet dose pack | $1,513.16 (Drugs.com) | $1,513.16 (Drugs.com) | $1,513.16 (Drugs.com) |
| Cash, 20-tablet moderate-renal dose pack | $1,469.32 (Drugs.com) | $1,491.24 (midpoint) | $1,513.16 (Drugs.com) |
| Cash, 11-tablet severe-renal dose pack | $1,513.16 (Drugs.com) | $1,513.16 (Drugs.com) | $1,513.16 (Drugs.com) |
| What the pharmacy paid, per course | $1,473.64 (NADAC) | $1,475.56 (NADAC) | $1,477.02 (NADAC) |
| Pharmacist assessment to get the prescription | $0 if your plan covers it (CVS) | not published | $60 (CVS) |
Three of those rows carry a single published figure rather than a spread, which is itself informative. Generic competition is what normally creates a price range, and Paxlovid has none.
The acquisition row is the tell. NADAC prices the 30-tablet pack at $49.23389 per tablet, the 20-tablet pack at $73.80069, and the 11-tablet renal pack at $133.96709. Multiply each by its carton count and you land at $1,477.02, $1,476.01 and $1,473.64. Pfizer prices the course, not the pill, and the cash price at the counter sits only slightly above what the pharmacy paid.
What Drives the Price
There is no generic
Paxlovid is nirmatrelvir co-packaged with ritonavir, and only Pfizer sells it in the United States. Ritonavir on its own has been generic for years and costs very little, but the combination product is protected, so nothing pulls the price down. Compare that with amoxicillin or doxycycline, where a dozen manufacturers compete and a full course runs under $15.
The course is the unit
The FDA label on DailyMed lists three dose packs: 30 tablets in ten blister cards, 20 tablets in ten blister cards, and 11 tablets in one card for severe renal impairment. All three price out within about $4 of each other in federal acquisition data. Fewer tablets does not mean a smaller bill.
The federal program masks the list price
Because HHS’s assistance program has been supplying free courses to uninsured and government-insured patients, most patients never see the list price. That is also why the number surprises people when they do see it. CVS’s own COVID antiviral page, read September 3, 2026, still states flatly that “there is no cost to the patient for the oral antiviral medication Paxlovid, if prescribed,” while listing a $60 fee for the pharmacist assessment that produces the prescription.
The visit is billed separately
Whatever the drug costs, someone has to write the prescription, and that is its own charge. CVS’s $60 pharmacist assessment is the cheap end. A cash urgent care visit or a self-pay doctor visit typically costs more. CVS also notes it collects the $60 even when the assessment does not result in a prescription.
Timing is a hard constraint
Antivirals for COVID are only prescribed within a narrow window after symptoms start, which CVS’s eligibility screener describes as five days. That compresses your shopping time to roughly zero, which is exactly the situation in which people overpay. Knowing the program exists before you are sick is the practical version of price shopping here.
Cash Price vs. Insurance
For most prescription drugs, self-pay and insurance are two competing routes and you pick the cheaper one. Paxlovid is different, because the cheapest route is neither.
If you are uninsured, on Medicare, or on Medicaid, Pfizer’s PAXCESS page directs you to the US Government Patient Assistance Program, an HHS-sponsored program Pfizer operates. The page states that eligible government-insured and uninsured patients can access Paxlovid for free through December 31, 2026. Enrollment happens at the PAXCESS patient portal or by phone, and Pfizer publishes a pharmacy finder for locations participating in the program.
If you have commercial insurance, the route is the co-pay card. Pfizer’s page says eligible commercially insured patients may pay as little as $0, with savings capped at $1,000 annually. The card is enrolled or activated online, and a rebate form exists for people who already paid.
If you have Medicare or Medicaid, you cannot legally use the manufacturer co-pay card, which is why Pfizer routes those patients to the government program instead. CVS separately notes that pharmacists cannot perform its paid Paxlovid assessment for Medicaid members at all, and that Medicare beneficiaries have to self-pay the $60 assessment fee.
The one group that can genuinely get hit with the full $1,513 is someone who is uninsured, does not know the program exists, and fills the prescription at a retail counter without asking. That is an avoidable outcome, not a market price.
How to Pay Less
Enroll in the US Government Patient Assistance Program first. It is the single highest-value step and it is worth roughly $1,500. Pfizer’s PAXCESS pages point uninsured, Medicare and Medicaid patients to the portal at paxlovid.iassist.com or a phone line for enrollment. The page states the program runs through December 31, 2026, so treat that date as a real deadline rather than a formality.
Ask the pharmacy to run the program before it runs your card. A pharmacy that is set up for the program can bill it directly. Pfizer publishes a pharmacy finder specifically to identify participating locations, which means not every counter is one. If the first pharmacy says the cash price is $1,500, that is a signal to call another one, not a final answer.
Use the co-pay card if you have commercial coverage. Eligible commercially insured patients can get to as little as $0, and a rebate form exists if you already paid out of pocket. Missing this is the most common way an insured person overpays.
Price the prescribing visit separately from the drug. The $60 pharmacist assessment at CVS is far cheaper than an emergency room and usually cheaper than urgent care. If you need a low-cost route to a prescriber, community health centers and sliding-scale clinics charge based on income, and our fair price checker will show you what a cash visit should run in your area.
Compare discount cards only as a fallback. Discount cards are the standard tool for generics and they are worth understanding, so read our GoodRx vs. SingleCare comparison before you rely on one. On a single-source brand drug like Paxlovid, though, expect a card to shave a modest percentage at best. The assistance program beats it by an order of magnitude.
If you already got billed, negotiate. A four-figure pharmacy charge for a drug that has a free federal program behind it is a strong case for a retroactive adjustment or a rebate. Our guide to negotiating medical bills covers how to open that conversation and what to ask for in writing.
The Bottom Line
Paxlovid’s list price is real and it is high: about $1,469 to $1,513 in cash at a pharmacy counter in September 2026, against roughly $1,476 that the pharmacy itself paid. But the price most people should pay is $0, and the mechanism that makes it $0 has a published expiration date of December 31, 2026.
That makes Paxlovid a rare case where the useful action is administrative rather than financial. Find out whether you qualify for the federal program, enroll, and know which nearby pharmacy participates, ideally before you are sick enough to need it. If you want a broader look at what respiratory-season prescriptions run as a cash payer, our guides to Tamiflu and azithromycin cover the same ground for flu and bacterial infections.